Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748114 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13283950 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13266447 | 0.80 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19756453 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22827192 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27380454 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14224176 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12250822 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20178652 | 0.76 | SHBG (0.39) | — | |
| SCHEMBL17067969 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974423-A1 | INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HWANG SUNG YEOUN (KR) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | CHRNB2 754/4885CHRNA4 1467/4885CHRNB4 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.